Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/118187
Registo completo
Campo DCValorIdioma
dc.creatorPérez-Cabezas, B-
dc.creatorCecílio, P-
dc.creatorRobalo, AL-
dc.creatorSilvestre, R-
dc.creatorCarrillo, E-
dc.creatorMoreno, J-
dc.creatorSan, Martín J-
dc.creatorVasconcellos, R-
dc.creatorCordeiro-da-Silva, A-
dc.date.accessioned2019-01-08T09:55:02Z-
dc.date.available2019-01-08T09:55:02Z-
dc.date.issued2016-
dc.identifier.issn1664-3224-
dc.identifier.urihttps://repositorio-aberto.up.pt/handle/10216/118187-
dc.description.abstractThe complexity of Leishmania-host interactions, one of the main leishmaniasis issues, is yet to be fully understood. We detected elevated IL-27 plasma levels in European patients with active visceral disease caused by Leishmania infantum, which returned to basal levels after successful treatment, suggesting this cytokine as a probable infection mediator. We further addressed this hypothesis recurring to two classical susceptible visceral leishmaniasis mouse models. BALB/c, but not C57BL/6 mice, showed increased IL-27 systemic levels after infection, which was associated with an upregulation of IL-27p28 expression by dendritic cells and higher parasite burdens. Neutralization of IL-27 in acutely infected BALB/c led to decreased parasite burdens and a transient increase in IFN-¿ + splenic T cells, while administration of IL-27 to C57BL/6 promoted a local anti-inflammatory cytokine response at the site of infection and increased parasite loads. Overall, we show that, as in humans, BALB/c IL-27 systemic levels are infection dependently upregulated and may favor parasite installation by controlling inflammation.-
dc.description.sponsorshipThis work was supported by Fundação para a Ciência e Tecnologia (FCT)/Ministério da Educação e da Ciência (MEC), co-funded by FEDER under the PT2020 Partnership Agreement through the Research Unit NO. 4293; by European Community’s Seventh Framework Programme under grant agreement No. 603182 (Project MuLeVaClin) and by the ISCIII-AES project (project reference PI13/00440). PC and BP-C are supported by fellowships from the European Community’s Seventh Framework Programme under grant agreements No. 603182 (Project MuLeVaClin) and No. 603240-2 (Project NMTryPI), respectively.-
dc.language.isoeng-
dc.publisherFrontiers Media-
dc.relation.ispartofFrontiers in Immunology, vol.7: 478-
dc.rightsopenAccess-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectIL-27-
dc.subjectLeishmania Infantum-
dc.subjectHuman-
dc.subjectImmune Regulation-
dc.subjectMouse Models-
dc.titleInterleukin-27 early impacts Leishmania infantum infection in mice and correlates with active visceral disease in humans-
dc.typeArtigo em Revista Científica Internacional-
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde-
dc.identifier.doi10.3389/fimmu.2016.00478-
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fimmu.2016.00478/full-
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Begona_IL27_Front Immunol_2016.pdf3.98 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons